Clinical trials are in progress to test the efficacy of the casein kinase inhibitor CX-4945 in multiple cancer types such as multiple myeloma and cholangiocarcinoma (clinicaltrials.gov). This evidence concerns the gene PDIK1L and cholangiocarcinoma.